Selpercatinib vs Vepafestinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: RET · full Non-Small Cell Lung Cancer pipeline

Selpercatinib · Retevmo

Marketed by Eli Lilly and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04194944 · Phase 3 · active, not recruiting

LIBRETTO-431 randomised 261 patients with RET fusion-positive NSCLC to selpercatinib or platinum-pemetrexed chemotherapy with or without pembrolizumab. Treatment was open-label, but progression was assessed by blinded independent central review. The primary endpoint, progression-free survival, was met (HR 0.465, 95% CI 0.309 to 0.699, p=0.0002 against chemotherapy plus pembrolizumab); the open-label design keeps the grade at moderate.

Next expected readout: December 2026 · NCT04268550 (registry estimate)

Reported efficacy

Event-Free Survival (EFS) (Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)): Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026) (met)

Result source: NCT04819100

Vepafestinib

Developed by Taiho Pharmaceutical

Phase 1/2 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2030 · NCT04683250 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSelpercatinibVepafestinib
PFS, median24.8 vs 11.2vs Pemetrexed and Platinum With Pembrolizumabn 129NCT04194944
1 other result
—Not reported
OS, median33.0n 159NCT04194944—Not reported
ORR83.7% vs 65.1%vs Pemetrexed and Platinum With Pembrolizumabn 129NCT04194944
1 other result
  • 83.6% vs 62.7% n 159 · Phase 3 · secondary NCT04194944
—Not reported
Duration of response, median24.2 vs 11.5vs Pemetrexed and Platinum With Pembrolizumabn 108NCT04194944
1 other result
—Not reported

PFS, median

Selpercatinib
24.8 vs 11.2vs Pemetrexed and Platinum With Pembrolizumabn 129NCT04194944
1 other result
Vepafestinib
—Not reported

OS, median

Selpercatinib
33.0n 159NCT04194944
Vepafestinib
—Not reported

ORR

Selpercatinib
83.7% vs 65.1%vs Pemetrexed and Platinum With Pembrolizumabn 129NCT04194944
1 other result
  • 83.6% vs 62.7% n 159 · Phase 3 · secondary NCT04194944
Vepafestinib
—Not reported

Duration of response, median

Selpercatinib
24.2 vs 11.5vs Pemetrexed and Platinum With Pembrolizumabn 108NCT04194944
1 other result
Vepafestinib
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Vepafestinib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Selpercatinib: 3 of 4 rows · Vepafestinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSelpercatinib
Dropout rate
61.6%
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
—
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Serious AEs
34.8%
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
aspartate aminotransferase increased 61.4%
alanine aminotransferase increased 60.1%
hypertension 48.1%
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Selpercatinib

PFS 24.84 vs 11.17 Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
24.84 vs 11.17 Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Disease Control 89.1% (n=129) vs 84.3% (n=83) Pemetrexed and Platinum With Pembrolizumab
responder rate · % of participants
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
89.3% (n=159) vs 82.4% (n=102) Pemetrexed and Platinum With or Without Pembrolizumab
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
PFS2 NA vs NA Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs NA Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
ORR 83.7% (n=129) vs 65.1% (n=83) Pemetrexed and Platinum With Pembrolizumab
responder rate · % of participants
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
83.6% (n=159) vs 62.7% (n=102) Pemetrexed and Platinum With or Without Pembrolizumab
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Duration of Response 24.18 vs 11.47 Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
24.18 vs 11.99 Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Overall Survival NA vs NA Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
33.05 vs NA Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Intracranial ORR 81% (n=21) vs 57.1% (n=21) Pemetrexed and Platinum With Pembrolizumab
responder rate · % of participants
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
84% (n=25) vs 50% (n=26) Pemetrexed and Platinum With or Without Pembrolizumab
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Intracranial Duration of Response NA vs NA Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs 13.4 Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration Pulmonary Symptoms NA vs 1.9 Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs 1.6 Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Time to CNS Progression NA vs NA Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs NA Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Selpercatinib's landscape · Vepafestinib's landscape